Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • MedCom GmbH and...

    MedCom GmbH and Hitachi Medical Systems Europe Announce an Agreement to Distribute BiopSee®, MedCom's Fusion Imaging System for Stereotactic, Navigated, Targeted Prostate Biopsy & Therapy Guidance, for use in Conjunction With Hitachi Ultrasound Systems

    Written by savita thakur thakur Published On 2016-03-12T13:05:16+05:30  |  Updated On 12 March 2016 1:05 PM IST
    MedCom GmbH and Hitachi Medical Systems Europe Announce an Agreement to Distribute BiopSee®, MedComs Fusion Imaging System for Stereotactic, Navigated, Targeted Prostate Biopsy & Therapy Guidance, for use in Conjunction With Hitachi Ultrasound Systems
    Switzerland: MedCom GmbH, Darmstadt, Germany and Hitachi Medical Systems Europe, Zug, Switzerland, announce an agreement to distribute through Hitachi's subsidiaries sales network in Europe BiopSee®, MedCom's fusion imaging system for stereo tactic, navigated, targeted prostate biopsy & therapy guidance, for use in conjunction with Hitachi ultrasound systems. Hitachi will be the sole distributor of the BiopSee
    ®
    products in this territory for Hitachi's installed base and when bundled with Hitachi's products.

    BiopSee® fusion imaging station combines multi-parametric MRI with real-time ultrasound. It offers thereby exceptional precision in stereotactic and navigated interventions with intuitive workflow that can bring state-of-the-art technology to everyday urology practice. The BiopSee®software supports 3D ultrasound image acquisition, rigid/elastic fusion with MRI, planning, navigation, reporting of interventional procedures, and interfaces to focal therapy devices. An electronically tracked stepper provides millimetric precision for a transperineal approach, while a magnetically tracked freehand probe can be used for navigated TRUS and abdominal procedures.

    The combined forces of the MedCom BiopSee® system, powered by urology's Gold Standard ultrasound from Hitachi, offer "the best of both worlds" to medical practitioners and patients alike: the superior quality of Hitachi's ultrasound with its wide variety of available transducers together with BiopSee's® intuitive workflow, documentation and reporting, opening new possibilities for future patient management. '
    I am excited at the potential of this partnership to bring new and innovative clinical solutions to our customers
    ', said Mr. Chris Japp, President & CEO of Hitachi Medical Systems Europe.

    The agreement allows Hitachi to respond rapidly to market needs providing flexible solutions for improved diagnostic and therapeutic image guidance in the field of prostate management.

    Hitachi Medical Systems Europe are showcasing the combined Noblus and BiopSee systems at the 2016 European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth # E16. In addition you can see & test both systems at the ESU/ESUT/ESUI Hands-on training in MRI Fusion, ICM building, Hall B0, level 0, Sunday, March 13th, 10.00-12.00 (HOT 29) and 14.00-16.00 (HOT 30).
    DarmstadtEuropean Association of UrologyHitachi Medical SystemsMedCom GmbHMr. Chris JappMRITRUS
    Source : PRNewswire

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok